课题基金 / 基金详情

ACTG--ATOVAQUONE /AZITHROMYCIN COMPARED TO TRIMETHOPRIM-SULFAMETHOXAZOLE

ACTG--ATOVAQUONE /AZITHROMYCIN COMPARED TO TRIMETHOPRIM-SULFAMETHOXAZOLE
ACTG--阿托伐醌/阿奇霉素与甲氧苄啶-磺胺甲恶唑相比
批准号：
6245189
负责人：
Ram Yogev
金额：
$1.2万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-07-15 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6245189
关键词：
AIDS therapy atovaquone azithromycin clinical research clinical trials combination chemotherapy disease /disorder prevention /control drug interactions drug screening /evaluation drug tolerance human subject human therapy evaluation longitudinal human study opportunistic infections outcomes research pharmacokinetics secondary infection sulfamethoxazole trimethoprim

项目摘要

项目成果

Ram Yogev的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The purpose of this study is to determine the comparability of Azithromycin plus m-Atovaquone to TMP/SMX in the prevention of serious bacterial infections; to determine and compare the long-term safety and tolerance of TMP/SMX vs. m-Atovaquone/Azithromycin; and to look at the likelihood of a pharmacokinetic interaction between m-Atovaquone and Azithromycin. Targeted accrual for this study is a total of 690 patients nationwide, with 340 patients on each treatment regime.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Units for HIV/AIDS Clinical Trials Networks
Units for HIV/AIDS Clinical Trials Networks
Units for HIV/AIDS Clinical Trials Networks
Units for HIV/AIDS Clinical Trials Networks
海外基金